Biosimilar User Fees Discounted To Begin Second Round

After adjusting for expected workload, US FDA reduces biosimilar user fee revenue target, which lowered application fees.

FDA entrance sign 2016
Biosimilar application fees will drop significantly in fiscal year 2018.

More from Biosimilars

More from Biosimilars & Generics